Northeast India's First Startup India-Recognized Pharma Company Raises ₹1.5 Crore, Eyes National Expansion

Progressive Molecules Pvt Ltd has established itself as a trailblazer in Northeast India's healthcare sector, becoming the region's first pharmaceutical venture to receive Startup India recognition. The company, steered by a leadership team comprising Anupriya Deb, Mammon Ara Sadial, Priya Banik, and Sandeep Kumar Mollick, is working to narrow the divide between cutting-edge medical breakthroughs and equitable healthcare access for ordinary citizens.

Building from the Ground Up

The company's trajectory reflects determination and strategic geographic growth. Progressive Molecules first took root in the Barak Valley, where it focused on optimizing pharmaceutical supply chains and guaranteeing quality access to medicines. Recognizing the distinct healthcare obstacles presented by the Northeast's terrain, the leadership team extended their footprint into Mizoram and Tripura. Through careful management of supply chain complexities and cultivation of community partnerships, the organization succeeded in delivering critical pharmaceutical products to isolated regions across both states.

The company has now entered a fresh phase of expansion, formally launching operations in Assam's Brahmaputra Valley. This move signals Progressive Molecules' evolution from a regionally focused enterprise into a nationally competitive player.

Capitalizing on Growth Momentum

The pharmaceutical sector has responded with enthusiasm to Progressive Molecules' trajectory. The company recently completed a seed funding round, securing ₹1.5 crore at a post-money valuation of ₹21.5 crore.

The newly raised capital will be channeled toward three key areas:

• Research & Development: Strengthening the molecular composition of upcoming formulations
• Infrastructure: Broadening the distribution network throughout the Brahmaputra Valley
• Product Launches: Introducing innovative health supplements to mainstream consumers

Introducing FILOMEGA3

Alongside its geographic expansion, Progressive Molecules has unveiled FILOMEGA3, its marquee offering.

The market has long been divided between low-efficacy supplements and costly imported alternatives. FILOMEGA3 disrupts this landscape by delivering pharmaceutical-grade Omega-3 at an accessible price point. Through advanced molecular optimization, Progressive Molecules is making cardiovascular and cognitive health support available to Indian households as an everyday product rather than a premium option.

Community-Centered Mission

For the company's board members, Progressive Molecules represents more than commercial enterprise—it embodies a commitment to community welfare. The organization pursues its "Health for All" vision through sustained grassroots initiatives:

• Complimentary Health Camps: Regular medical screenings and essential medicines for disadvantaged populations
• Online Doctor Consultations: Virtual educational sessions addressing disease awareness and treatment strategies

These programs extend the company's impact beyond product delivery, fostering broader health literacy and preventive care awareness across communities.

Looking Forward

With Startup India backing and fresh capital in hand, Progressive Molecules exemplifies the innovation potential flourishing in Northeast India. The company's leadership is demonstrating that sophisticated pharmaceutical development and cutting-edge health solutions can emerge from the region's entrepreneurial landscape, challenging conventional assumptions about India's innovation geography.